Paper37627273
Chronic Hepatitis B Infection: New Approaches towards Cure.
Ogunnaike M and 8 others. Biomolecules, 2023. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Chronic Hepatitis B Infection: New Approaches towards Cure. Papers, record 37627273. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37627273
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Hepatitis B | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| DNA, Viral | |
| Antiviral Agents |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 DK135817 | NIDDK NIH HHS | United States | R01DK135817 | PubMed and NIH | NIH RePORTER |
| K01 AA026864 | NIAAA NIH HHS | United States | K01AA026864 | PubMed and NIH | NIH RePORTER |
| R01 AA027189 | NIAAA NIH HHS | United States | R01AA027189 | PubMed and NIH | NIH RePORTER |
| P50 AA030407 | NIAAA NIH HHS | United States | P50AA030407 | PubMed and NIH | NIH RePORTER |
| R01 AI163042 | NIAID NIH HHS | United States | R01AI163042 | PubMed and NIH | NIH RePORTER |
References158
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19399806 | Benefits and risks of interferon therapy for hepatitis B. | Hepatology | 2009 | https://conductscience.org/library/papers/19399806 | PubMed |
| 2 | 30506691 | Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. | Aliment Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30506691 | PubMed |
| 3 | 36686591 | Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status. | JHEP Rep | 2023 | https://conductscience.org/library/papers/36686591 | PubMed |
| 4 | 32278307 | Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. | Mol Ther Nucleic Acids | 2020 | https://conductscience.org/library/papers/32278307 | PubMed |
| 5 | 31147612 | The next generation of CRISPR-Cas technologies and applications. | Nat Rev Mol Cell Biol | 2019 | https://conductscience.org/library/papers/31147612 | PubMed |
| 6 | 36960800 | Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. | Hepatology | 2023 | https://conductscience.org/library/papers/36960800 | PubMed |
| 7 | 24690881 | A guide to genome engineering with programmable nucleases. | Nat Rev Genet | 2014 | https://conductscience.org/library/papers/24690881 | PubMed |
| 8 | 36820558 | Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B. | Medicine (Baltimore) | 2023 | https://conductscience.org/library/papers/36820558 | PubMed |
| 9 | 36404234 | Highly dynamic changes of regional HBV epidemiology over two decades. | Dig Liver Dis | 2023 | https://conductscience.org/library/papers/36404234 | PubMed |
| 10 | 34303003 | Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. | Clin Res Hepatol Gastroenterol | 2022 | https://conductscience.org/library/papers/34303003 | PubMed |
| 11 | 27132172 | First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. | J Hepatol | 2016 | https://conductscience.org/library/papers/27132172 | PubMed |
| 12 | 33333207 | Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. | J Hepatol | 2021 | https://conductscience.org/library/papers/33333207 | PubMed |
| 13 | 28647765 | Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. | Abdom Radiol (NY) | 2018 | https://conductscience.org/library/papers/28647765 | PubMed |
| 14 | 18240869 | Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. | Antivir Ther | 2007 | https://conductscience.org/library/papers/18240869 | PubMed |
| 15 | 35238624 | Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes. | CRISPR J | 2022 | https://conductscience.org/library/papers/35238624 | PubMed |
| 16 | 33395488 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33395488 | PubMed |
| 17 | 33341047 | Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/33341047 | PubMed |
| 18 | 29940226 | Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. | Eur J Pharm Biopharm | 2018 | https://conductscience.org/library/papers/29940226 | PubMed |
| 19 | 25402233 | Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. | AIDS Res Hum Retroviruses | 2015 | https://conductscience.org/library/papers/25402233 | PubMed |
| 20 | 34531390 | Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. | Nat Commun | 2021 | https://conductscience.org/library/papers/34531390 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42503913 | [Clinical significance and occurrence mechanism of hepatitis B virus DNA integration]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42503913 | PubMed |
| 42467124 | AURKA regulates HBV-induced hepatic stellate cell inflammation and liver fibrosis by modulating K48-linked ubiquitination and proteasomal degradation of TLR3. | J Bioenerg Biomembr | 2026 | https://conductscience.org/library/papers/42467124 | PubMed |
| 42243721 | Antiviral therapy and hidden predictors of postoperative outcomes in hepatocellular carcinoma. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42243721 | PubMed |
| 41830105 | HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis. | J Viral Hepat | 2026 | https://conductscience.org/library/papers/41830105 | PubMed |
| 41676540 | Adenine Base Editing Potently Suppresses Hepatitis B Surface Antigen Expression and Inhibits Hepatitis D Virus Release. | bioRxiv | 2026 | https://conductscience.org/library/papers/41676540 | PubMed |
| 41341015 | Knowledge, Attitudes, and Practices Regarding Hepatitis B and Liver Cancer Among Liver Cancer Patients and Their Families in China. | Cancer Manag Res | 2025 | https://conductscience.org/library/papers/41341015 | PubMed |
| 40872772 | The Evolution of Cell Culture Systems to Study Hepatitis B Virus Pathogenesis and Antiviral Susceptibility. | Viruses | 2025 | https://conductscience.org/library/papers/40872772 | PubMed |
| 40749058 | A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression. | Sci Adv | 2025 | https://conductscience.org/library/papers/40749058 | PubMed |
| 40687725 | An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40687725 | PubMed |
| 40575574 | Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40575574 | PubMed |
| 40143195 | Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound's Drug Discovery and Repurposing for HBV Therapy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40143195 | PubMed |
| 40092015 | Chronic Hepatitis B Virus Persistence: Mechanisms and Insights. | Cureus | 2025 | https://conductscience.org/library/papers/40092015 | PubMed |
| 39980283 | Clinical and In vitro Data Shed New Light on the Therapeutic Advantages of Black Seeds (Nigella sativa) for the Treatment of Hepatitis C and Hepatitis B Viral Infections. | Infect Disord Drug Targets | 2025 | https://conductscience.org/library/papers/39980283 | PubMed |
| 39860969 | Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention. | Pathogens | 2024 | https://conductscience.org/library/papers/39860969 | PubMed |
| 39804828 | Pharmacophore modeling and QSAR analysis of anti-HBV flavonols. | PLoS One | 2025 | https://conductscience.org/library/papers/39804828 | PubMed |
| 39572840 | Hepatitis B and D virus entry. | Nat Rev Microbiol | 2025 | https://conductscience.org/library/papers/39572840 | PubMed |
| 39459899 | Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics. | Viruses | 2024 | https://conductscience.org/library/papers/39459899 | PubMed |
| 38858185 | [A new concept from a global perspective for expanding the treatment of chronic hepatitis B]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/38858185 | PubMed |
| 38668246 | Prospects for Controlling Hepatitis B Globally. | Pathogens | 2024 | https://conductscience.org/library/papers/38668246 | PubMed |
| 38612717 | Insights into the Management of Chronic Hepatitis in Children-From Oxidative Stress to Antioxidant Therapy. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612717 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37627273
GET https://conductscience.org/api/papers/v1/37627273/references?page=2